Home >> Signaling Pathways >> JAK/STAT Signaling

JAK/STAT Signaling

Products for  JAK/STAT Signaling

  1. Cat.No. Product Name Information
  2. GC68440 EGFR-IN-69 EGFR-IN-69  Chemical Structure
  3. GC68430 Selatinib Selatinib  Chemical Structure
  4. GC68378 GDC-4379 GDC-4379  Chemical Structure
  5. GC68321 O-Desmethyl gefitinib-d8 O-Desmethyl gefitinib-d8  Chemical Structure
  6. GC68304 Margetuximab Margetuximab  Chemical Structure
  7. GC68000 JAK-IN-23 JAK-IN-23  Chemical Structure
  8. GC67958 HP590 HP590  Chemical Structure
  9. GC67867 VVD-118313 VVD-118313  Chemical Structure
  10. GC67860 JBJ-09-063 TFA JBJ-09-063 TFA  Chemical Structure
  11. GC67779 STX-0119 STX-0119  Chemical Structure
  12. GC67759 Lapatinib-d4 Lapatinib-d4  Chemical Structure
  13. GC67749 Amivantamab Amivantamab  Chemical Structure
  14. GC67706 LY5 LY5  Chemical Structure
  15. GC67690 JBJ-09-063 hydrochloride JBJ-09-063 hydrochloride  Chemical Structure
  16. GC52293 STAT3 Inhibitor 4m A STAT3 inhibitor STAT3 Inhibitor 4m  Chemical Structure
  17. GC66432 EAI001 EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer. EAI001  Chemical Structure
  18. GC66428 EGFR-IN-5 EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively. EGFR-IN-5  Chemical Structure
  19. GC66405 Panitumumab Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer. Panitumumab  Chemical Structure
  20. GC66333 Panitumumab (anti-EGFR) Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer. Panitumumab (anti-EGFR)  Chemical Structure
  21. GC66329 NDI-034858 NDI-034858 is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM. NDI-034858  Chemical Structure
  22. GC65992 FGFR2-IN-3 FGFR2-IN-3 is an orally active selective inhibitor of FGFR2. FGFR2-IN-3  Chemical Structure
  23. GC65991 FGFR2-IN-3 hydrochloride FGFR2-IN-3 hydrochloride is an orally active selective inhibitor of FGFR2. FGFR2-IN-3 hydrochloride  Chemical Structure
  24. GC65974 EGFR-IN-9 EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity. EGFR-IN-9  Chemical Structure
  25. GC65572 EGFR Protein Tyrosine Kinase Substrate EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate. EGFR Protein Tyrosine Kinase Substrate  Chemical Structure
  26. GC65453 JAK-IN-3 JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively. JAK-IN-3  Chemical Structure
  27. GC65436 JND3229 JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma. JND3229  Chemical Structure
  28. GC65405 JAK2-IN-6 JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective JAK2 inhibitor with an IC50 of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells. JAK2-IN-6  Chemical Structure
  29. GC65387 Tyk2-IN-5 Tyk2-IN-5 (compound 6) is a highly potent, selective and orally active Tyk2 inhibitor and targets the JH2 domain, with a Ki of 0.086 nM for Tyk2 JH2 and an IC50 of 25 nM for IFNα. Tyk2-IN-5  Chemical Structure
  30. GC65344 STAT5-IN-2 STAT5-IN-2 is a STAT5 inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect. STAT5-IN-2  Chemical Structure
  31. GC65310 TAS0728 TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC50 of 13 nM. TAS0728 also shows IC50s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMX、HER4、BLK、EGFR、JAK3、SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2 TAS0728  Chemical Structure
  32. GC65278 PIM1-IN-1 PIM1-IN-1 is a potent and highly selective PIM1/3 inhibitor, with IC50s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC50 of 262 nM. PIM1-IN-1 shows no obvious effect on FLT3 or hERG binding. Antiproliferative and anti-cancer activity. PIM1-IN-1  Chemical Structure
  33. GC65201 Quercetagetin Quercetagetin (6-Hydroxyquercetin) is a flavonoid. Quercetagetin  Chemical Structure
  34. GC65020 Danvatirsen Danvatirsen is an antisense oligonucleotide targeting STAT3 with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth. Danvatirsen  Chemical Structure
  35. GC64959 JAK/HDAC-IN-1 JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC50s of 4 and 2 nM for JAK2 and HDAC, respectively. JAK/HDAC-IN-1  Chemical Structure
  36. GC64891 YM-341619 YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC50 of 0.70 nM. YM-341619  Chemical Structure
  37. GC64774 SEL24-B489 SEL24-B489 is a potent, type I, orally active, dual PIM and FLT3-ITD inhibitor, with Kd values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively. SEL24-B489  Chemical Structure
  38. GC64770 Oritinib Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFRWT, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750 and EGFRd746-750/T790M kinases, with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively. Oritinib  Chemical Structure
  39. GC64710 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate. MC-Val-Cit-PAB-Amide-TLR7 agonist 4  Chemical Structure
  40. GC64701 Povorcitinib Povorcitinib is a potent and selective inhibitor of JAK1. Povorcitinib  Chemical Structure
  41. GC64700 Povorcitinib phosphate Povorcitinib phosphate  Chemical Structure
  42. GC64497 EGFR-IN-17 EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance. EGFR-IN-17  Chemical Structure
  43. GC64398 Almonertinib mesylate Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer. Almonertinib mesylate  Chemical Structure
  44. GC64372 Lorpucitinib Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease. Lorpucitinib  Chemical Structure
  45. GC64302 BAY 2476568 BAY 2476568 is a potent and selective EGFR inhibitor, with IC50s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG). BAY 2476568  Chemical Structure
  46. GC64108 Ifidancitinib Ifidancitinib (ATI-50002) is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib  Chemical Structure
  47. GC64039 Disitamab vedotin Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity. Disitamab vedotin  Chemical Structure
  48. GC64017 Befotertinib Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC). Befotertinib  Chemical Structure
  49. GC63910 BLU-945 BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC). BLU-945  Chemical Structure
  50. GC63864 (E/Z)-Zotiraciclib hydrochloride (E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, JAK2, and FLT3 inhibitor. (E/Z)-Zotiraciclib hydrochloride  Chemical Structure
  51. GC63797 (S)-Sunvozertinib (S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK. (S)-Sunvozertinib  Chemical Structure
  52. GC63204 Stafib-2 Stafib-2 is a potent and selctive inhibitor of the transcription factor STAT5b, with an IC50 of 82 nM and 1.7 μM for STAT5b and STAT5a, respectively. Stafib-2  Chemical Structure
  53. GC63203 Stafia-1-dipivaloyloxymethyl ester Stafia-1-dipivaloyloxymethyl ester (compound 27, 0-200 μM) decreases pSTAT5a expression significantly, and has no obvious inhibition on pSTAT5b. Stafia-1-dipivaloyloxymethyl ester  Chemical Structure
  54. GC49139 CAY10784 A STAT3 inhibitor CAY10784  Chemical Structure
  55. GC62559 Stafia-1 Stafia-1 is a potent STAT5a inhibitor (K i=10.9 μM, IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members. Stafia-1  Chemical Structure
  56. GC62272 AC-4-130 AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML). AC-4-130  Chemical Structure
  57. GC62254 Stafib-1 Stafib-1 is the first selective inhibitor of the STAT5b SH2 domain, with a Ki of 44 nM and an IC50 of 154 nM. Stafib-1  Chemical Structure
  58. GC61807 (E/Z)-AG490 (E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3. (E/Z)-AG490  Chemical Structure
  59. GC61627 Ochromycinone Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a STAT3 inhibitor. Ochromycinone  Chemical Structure
  60. GC61574 AS1810722 AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722  Chemical Structure
  61. GC61524 SC-43 SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects. SC-43  Chemical Structure
  62. GC48839 Nifuroxazide-d4 An internal standard for the quantification of nifuroxazide Nifuroxazide-d4  Chemical Structure
  63. GC47061 CAY10763 A dual inhibitor of IDO1 and STAT3 activation CAY10763  Chemical Structure
  64. GC46503 2-(1,8-Naphthyridin-2-yl)phenol 2-(1,8-Naphthyridin-2-yl)phenol is a selective enhancer of STAT1 transcription. 2-(1,8-Naphthyridin-2-yl)phenol can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells. 2-(1,8-Naphthyridin-2-yl)phenol  Chemical Structure
  65. GC60586 Angoline hydrochloride Angoline hydrochloride is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline hydrochloride inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation. Angoline hydrochloride  Chemical Structure
  66. GC60585 Angoline Angoline is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation. Angoline  Chemical Structure
  67. GC50343 HJC 0416 hydrochloride STAT3 inhibitor HJC 0416 hydrochloride  Chemical Structure
  68. GC39081 Reticuline Reticuline shows anti-inflammatory effects through JAK2/STAT3 and NF-κB signaling pathways. Reticuline  Chemical Structure
  69. GC39022 Tetramethylcurcumin Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin  Chemical Structure
  70. GC38737 AS2863619 free base AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 free base  Chemical Structure
  71. GC38736 AS2863619 A dual inhibitor of Cdk8 and Cdk19 AS2863619  Chemical Structure
  72. GC45756 Pimozide-d4 An internal standard for the quantification of pimozide Pimozide-d4  Chemical Structure
  73. GC38402 BI-4020 A fourth-generation and non-covalent EGFR tyrosine kinase inhibitor BI-4020  Chemical Structure
  74. GC38386 Golotimod hydrochloride Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod hydrochloride  Chemical Structure
  75. GC38350 Epertinib hydrochloride Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity. Epertinib hydrochloride  Chemical Structure
  76. GC38180 Cyasterone Cyasterone  Chemical Structure
  77. GC38125 Tyrphostin AG30 Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts. Tyrphostin AG30  Chemical Structure
  78. GC38081 Theliatinib Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. Theliatinib has an IC50 of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases. Anti-tumor activity. Theliatinib  Chemical Structure
  79. GC38044 Fraxinellone Fraxinellone  Chemical Structure
  80. GC38006 β-Hydroxyisovalerylshikonin Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC50s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells. β-Hydroxyisovalerylshikonin  Chemical Structure
  81. GC37971 ZM39923 ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM. ZM39923  Chemical Structure
  82. GC37933 WHI-P180 hydrochloride WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 hydrochloride  Chemical Structure
  83. GC37847 Tyk2-IN-8 Tyk2-IN-8 (Compound 3) is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8  Chemical Structure
  84. GC37846 Tyk2-IN-7 Tyk2-IN-7 (Compound 48) is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki. Tyk2-IN-7  Chemical Structure
  85. GC37689 STAT3-IN-3 STAT3-IN-3 is a potent and selective inhibitor of signal transducer and activator of transcription 3 (STAT3), with anti-proliferative activity. STAT3-IN-3 induces apoptosis in breast cancer cells. STAT3-IN-3 acts as a promising mitochondria-targeting STAT3 inhibitor for cancer research. STAT3-IN-3  Chemical Structure
  86. GC37688 STAT3-IN-1 STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis. STAT3-IN-1  Chemical Structure
  87. GC37651 SMI-16a A Pim-1 kinase inhibitor SMI-16a  Chemical Structure
  88. GC37575 Ruxolitinib sulfate Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib sulfate  Chemical Structure
  89. GC37568 RTC-5 RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling. RTC-5  Chemical Structure
  90. GC37523 RGB-286638 free base A multi-kinase inhibitor RGB-286638 free base  Chemical Structure
  91. GC37522 RGB-286638 A multi-kinase inhibitor RGB-286638  Chemical Structure
  92. GC36918 PIM-447 dihydrochloride A pan-Pim kinase inhibitor PIM-447 dihydrochloride  Chemical Structure
  93. GC36882 PF-06263276 PF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC50s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively. PF-06263276  Chemical Structure
  94. GC36819 Osimertinib dimesylate Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively. Osimertinib dimesylate  Chemical Structure
  95. GC36783 NVP-BSK805 dihydrochloride A potent, selective JAK2 inhibitor NVP-BSK805 dihydrochloride  Chemical Structure
  96. GC36699 Nazartinib mesylate Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively. Nazartinib mesylate  Chemical Structure
  97. GC36667 Mutated EGFR-IN-2 Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=<1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity. Mutated EGFR-IN-2  Chemical Structure
  98. GC36666 Mutated EGFR-IN-1 Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant. Mutated EGFR-IN-1  Chemical Structure
  99. GC36646 Momelotinib Mesylate Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3. Momelotinib Mesylate  Chemical Structure
  100. GC36366 JAK-IN-10 JAK-IN-10 is a JAK inhibitor. JAK-IN-10  Chemical Structure
  101. GC36365 JAK3 covalent inhibitor-1 JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs. JAK3 covalent inhibitor-1  Chemical Structure

Items 1 to 100 of 373 total

per page
  1. 1
  2. 2
  3. 3
  4. 4

Set Descending Direction